Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: Four cases

Diabetes Care

Volumn 34, Issue 11, 2011, Pages 2406-2409

  Basta, Giuseppe ^a   Montanucci, Pia ^a   Luca, Giovanni ^a   Boselli, Carlo ^a   Noya, Giuseppe ^a   Barbaro, Barbara ^b   Qi, Meirigeng ^b   Kinzer, Katie P ^b   Oberholzer, José ^b   Calafiore, Riccardo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HEMOGLOBIN A1C; HLA ANTIBODY; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PANCREAS ISLET CELL ANTIBODY; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; GLYCOSYLATED HEMOGLOBIN;

ANTIBODY DETECTION; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC PARAMETERS; MICROENCAPSULATED ISLET ALLOGRAFT; PANCREAS ISLET TRANSPLANTATION; PATIENT ASSESSMENT; PATIENT SAFETY; TREATMENT OUTCOME; ADULT; ALLOTRANSPLANTATION; BLOOD; CYTOLOGY; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; METHODOLOGY; PANCREAS ISLET;

ADULT; AUTOANTIBODIES; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84857099436     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0731     Document Type: Article

References (7)

1. Calafiore R, Basta G, Luca G, et al. Micro-encapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 2006;29:137-138 (Pubitemid 44033446)
2. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic liability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53:955-962 (Pubitemid 38436607)
3. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-238 (Pubitemid 30490390)
4. Thanos CG, Calafiore R, Basta G, et al. Formulating the alginate-polyornithine biocapsule for prolonged stability: evaluation of composition and manufacturing technique. J Biomed Mater Res A 2007;83:216-224 (Pubitemid 47435665)
5. Basta G, Sarchielli P, Luca G, et al. Optimized parameters for microencapsulation of pancreatic islet cells: an in vitro study clueing on islet graft immunoprotection in type 1 diabetes mellitus. Transpl Immunol 2004;13:289-296 (Pubitemid 39602596)
6. Vendrame F, Pileggi A, Laughlin E, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010;59:947-957
7. Vaithilingam V, Barbaro B, Oberholzer J, Tuch BE. Functional capacity of human islets after long-distance shipment and encapsulation. Pancreas 2011;40:247-252